Novartis AG Wins EU Approval For Glaucoma Drug Travatan

December 23, 2014 12:21 PM

4 0

Novartis announced today that the European Commission has approved Travatan, made by the company’s Alcon eye-care unit, to treat glaucoma in pediatric patients

Novartis AG (ADR) (NYSE:NVS) announced before US markets opened for trading Tuesday that the European Commission has approved its eye-drop solution, Travatan, to treat glaucoma in patients aged between two months to less than eighteen years, thus expanding the range of indications for which the medi...

Read more

To category page

Loading...